.png)
Materials
Presentations
Welcome, Forum Updates, Program Overview, and Acknowledgments
Mitchell Leus, Forum for Collaborative Research
Steering Committee Co-Chair Welcoming Remarks
Veronica Miller, Forum for Collaborative Research
Terry Wright, GSK
Session I: Towards Standardizing HBV Nomenclature: Implications for Drug Development & Beyond
Current issues with HBV nomenclature and a call for alignment
Su Wang, Center for Asian Health, Cooperman Barnabas Medical Center, Global Health Advisor, Hepatitis B Foundation
Evolving understanding on HBV infection and reframing stages
Mark Sulkowski, Johns Hopkins University
Learnings from Alaska Cohort
Brian McMahon, Alaska Native Tribal Health Consortium
Panel Perspectives
Eric Donaldson, FDA Center for Drug Evaluation and Research *
Poonam Mishra, FDA Center for Drug Evaluation and Research
Wendy Spearman, University of Cape Town
How Do We Move Forward
Markus Cornberg, Hannover Medical School *
Marc Ghany, NIH/NIDDK
Seng Gee Lim, National University Hospital, Singapore
Open Discussion: What are areas we need consensus on, any low hanging fruit, what are next steps?
All Meeting Participants
Session II: Novel Ways for Hepatocellular Carcinoma Surveillance in Patients with Chronic Hepatitis B
HCC Surveillance in HBV - Recognising and Stratifying Oncological Risk for Patients
Kosh Agarwal, King's College Hospital NHS Foundation
Industry Rapid Fire Talks: Novel Tools for HCC SurveillanceElle Grevstad, Exact Sciences
Shivani Mahajan, Helio GenomicsGeorge Rogge, FUJIFILM Healthcare Americas Corp.
Panel Discussion
Chari Cohen, Hepatitis B Foundation
Grace Dolman, GSK
Mark Sonderup, University of Cape Town
Open Discussion
All Meeting Participants
Session III: Immune Checkpoint Inhibitors Working Group
Immune Checkpoint Inhibitor (ICI) Treatment and Immune-related Adverse Events (IrAEs): Lessons Learned from Oncology for its Potential Use for Chronic Hepatitis B (CHB) Patients
Agustina Crespi, Toronto Center for Liver Disease
Mitchell Leus, Forum for Collaborative Research
Discussion on clinical insights and benefit-risk
Ed Gane, University of Auckland
Open Discussion
All Meeting Participants
Session IV: HDV Assay Development Working Group
Panel Discussion: What is a standard case definition of HDV infection?
Tom Battersby, Gilead Sciences
Kat Whitaker, FDA Center for Devices and Radiological Health*
Veronica Miller, Forum for Collaborative Research
Open Discussion
All Meeting Participants
* Indicates Remote Participation
